La vendita allo scoperto per Cartesian Therapeutics dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Cartesian Therapeutics. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Cartesian Therapeutics (NASDAQ:RNAC) Azioni, Report sulle vendite allo scoperto

Cartesian Therapeutics

Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. It leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function. Unlike DNA, mRNA degrades naturally over time without integrating into the cell's genetic material.

Cartesian Therapeutics, Inc. - Common Stock

Cartesian Therapeutics Inc

News

Offerings

State Street Plans Issuance Of $2.25B Of Senior Debt By Its Principal Banking Subsidiary, State Street Bank And Trust Company

IPOs

CGTL

Creative Global Technology Plans Pricing Of Its IPO Of 1.25M Ordinary Shares At $4.00 Per Share For Total Gross Proceeds Of $5M; To Commence Trading On November 26, Under The Ticker Symbol 'CGTL'

Eastman Kodak Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KODK#NYSE">KODK</a>) shares closed Monday&#8217;s session up more than 18% after the company announced plans to terminate its U.S. pension program. Here&#8217;s <a href="https://www.benzinga.com/quote/KODK/news">what you need to know.</a>
What To Know: In a new regulatory filing, Kodak said the Kodak Retirement Income Plan Trust entered into a purchase and sale agreement with Mastercard Foundation in which Mastercard will purchase certain private equity ownership interests and other illiquid assets. 
Kodak will sell the illiquid assets with a value of $764.4 million for a purchase price of $550.6 million in cash. Additional buyers will acquire $87.3 million in assets.
According to <a href="https://www.wsj.com/articles/kodak-prepares-to-terminate-u-s-pension-book-gain-of-more-than-500-million-d0cfb621?mod=lead_feature_below_a_pos3">The Wall Street Journal</a>, Kodak&#8217;s pension plan is overfunded, with $3.5 billion in assets and $2.3 billion in liabilities. The termination process will involve selling illiquid assets, settling liabilities and replacing the plan with a new retirement program. 
The termination is expected to result in a cash gain of $530 million to $585 million after taxes. Kodak plans to use these proceeds to reduce its $460 million in long-term debt, which includes a 12.5% term loan. Under its credit agreement, the company must reduce its debt balance to $200 million with proceeds of this size.
This move is aimed at improving Kodak's financial health, reducing interest expenses and investing in core business areas like pharmaceutical chemicals. The process is expected to take over a year and plan participants will retain the full value of their benefits through annuities or lump-sum payouts.
Kodak closed its latest quarter with $214 million in cash after reporting a quarterly profit of $18 million.
KODK Price Action: Eastman Kodak shares closed Monday at $6.24 after gaining 18.4% during regular trading hours, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://benzinga.slack.com/archives/D072651PB4K/p1727794380964569"><img loading="lazy" decoding="async" width="1024" height="542" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25161042/KODK-1024x542.png" alt="" class="wp-image-664229" style="width:483px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25161042/KODK-1024x542.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25161042/KODK-300x159.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25161042/KODK-768x407.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25161042/KODK.png 1464w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/entertainment/24/11/42174446/streaming-vinyl-propel-music-copyright-value-to-45-5-billion">Streaming, Vinyl Propel Music Copyright Value To $45.5 Billion</a></li>
</ul>
Photo: <a href="https://pixabay.com/users/jbooba-23039065/?utm_source=link-attribution&amp;utm_medium=referral&amp;utm_campaign=image&amp;utm_content=7452562">Gregor Mima</a> from Pixabay.

Movers

KODK

Kodak Stock Is Trading At 52-Week Highs: What's Going On?

Tim Draper, a prominent venture capitalist and cryptocurrency enthusiast, has made Bitcoin price predictions since 2014.
That year, Draper predicted Bitcoin to be $10,000 by the end of 2017. Despite skepticism, his forecast proved accurate, as Bitcoin hit $10,000 in November 2017 during its dramatic bull run.
In 2018, Draper forecast Bitcoin to reach $250,000 by the end of 2022. This bold prediction was not fully realized, though Bitcoin did reach an all-time high of approximately $69,000 in November 2021.
When Bitcoin failed to hit the target price in 2018, Draper extended the timeline to mid-2023. The futurist and investor based this target price on mass adoption, particularly by women and retail investors.
Draper said in an interview with Benzinga: "My first prediction was in 2014 when Bitcoin was at $180. I said that it would be $10,000 in three years. Sure enough, by the end of 2017, Bitcoin hit $10,000. Since then, I have not been as prescient. I thought Bitcoin would hit $250,000 by 2022! I think I am going to be three years off.&#8221; Draper added: &#8220;I think we can chalk those three years up to a weak government that regulated rather than encouraged new technologies. Our new government is more encouraging."
Since the U.S. presidential election in November, the crypto world has been celebrating with a decidedly more bullish outlook. Though many tokens have seen significant gains, including Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) and Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>), Bitcoin has taken center stage, reaching a record high of $99,000 on Nov. 21, the second all-time high of the month.
Benzinga asked Draper what his prediction was for Bitcoin with the end of 2024 rapidly approaching and he responded: "This is just the beginning! If you are asking about price prediction, I would say about Bitcoin will reach about $120,000 by end of year."
Benzinga asked Draper what drives his future forecasts for Bitcoin, he pointed to the superiority of the cryptocurrency over traditional fiat and long-term trends in usage.
"It is a long-term trend. Bitcoin is just better technology than using banks and governments as the trusted third party. It is transparent, global, open, keeps perfect records, etcetera. It will make the world wealthier. When retailers (for currency) and governments (for taxes) realize that Bitcoin will save them money on each transaction, then there will be a great incentive for everyone to use Bitcoin."
When asked for his prognostication for 2025, Draper said he is holding out for the $250,000 level and cited the proposed U.S. Bitcoin reserve as a contributing factor.
"Assuming a standard supply and demand curve, if there is a big buyer like that, the price will continue to rise. I think 2025 is the year Bitcoin will finally hit my mark of $250,000," Draper noted.
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42165734/bitcoin-etfs-registered-record-312-billion-net-inflows-last-week">Bitcoin ETFs Registered Record $3.12 Billion Net Inflows Last Week</a>
<h1 class="wp-block-heading">MicroStrategy Leads the Bitcoin Charge</h1>
Michael Saylor, co-founder of MicroStrategy, <a href="https://x.com/saylor/status/1861033309934862601">tweeted today</a><a href="https://x.com/saylor/status/1861033309934862601" target="_blank" rel="noopener"> </a>that the company acquired $5.4 billion in Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>), the single biggest purchase of the world's leading decentralized digital currency.
In the tweet, Saylor stated, "MicroStrategy has acquired 55,500 BTC for ~$5.4 billion at ~$97,862 per #bitcoin and has achieved BTC Yield of 35.2% QTD and 59.3% YTD. As of 11/24/2024, we hodl 386,700 $BTC acquired for ~$21.9 billion at ~$56,761 per bitcoin. $MSTR"
This is after the news that the company is making $500 million a day with its Bitcoin holdings, which Saylor said have appreciated by $5.4 billion over the past two weeks. Saylor predicted Bitcoin could reach $13 million by 2045, which would elevate its market cap to $250 trillion. 
<h1 class="wp-block-heading">Optimism Among Web3 Leaders</h1>
Nathan Berkley, CEO of Muhdo Health Limited, a health technology company specializing in DNA and epigenetic testing which incorporates cryptocurrency into its operations, has a bullish outlook on Bitcoin and independently concurs with Draper's forecast.
"I think we could see Bitcoin hit $120,000. With U.S. sentiment being positive to this market now, and understanding Web3 can have real impact, it's a great time to be in the space," Berkley noted.
Lisa Loud, executive director of Secret Network Foundation, a blockchain platform designed to enable privacy-preserving decentralized applications, said: "The Bitcoin of today is not the Bitcoin of 2020: we have a broader finance interest, politics, and uncertain regulatory changes. A conservative estimate would say it will end in the range of $92,000-115,000, but if we get a large opt-in from mainstream, we could blow this estimate out of the water."
Read Next: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42173367/shiba-inu-burn-rate-soars-487-in-a-day-what-is-going-on"> • Shiba Inu Burn Rate Soars 487% In A Day: What Is Going On?</a>
Photo: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Exclusives

Trading Ideas

$BTC

$ETH

$SOL

$USDT

$XRP

EXCLUSIVE: Tim Draper Predicts Bitcoin To Reach $120K By End Of 2024, $250K In 2025

The Q4 earnings report for Blue Bird (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLBD#NASDAQ">BLBD</a>) was released on Monday, November 25, 2024 at 04:00 PM.
Here's what investors need to know about the latest announcement.
<h3>Earnings</h3>
Blue Bird missed estimated earnings by -16.0%, reporting an EPS of $0.77 versus an estimate of $0.92.
Revenue was up $47.25 million from the same period last year.
<h3>Performance in Previous Earnings</h3>
During the previous quarter, the company beat on EPS by $0.4, leading to a 0.0% increase share price change the next day.
Here's a look at Blue Bird's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.51</td>
<td>0.48</td>
<td>0.37</td>
<td>0.48</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.91</td>
<td>0.89</td>
<td>0.91</td>
<td>0.66</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>328.60M</td>
<td>298.41M</td>
<td>275.13M</td>
<td>290.11M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>333.37M</td>
<td>345.92M</td>
<td>317.66M</td>
<td>302.96M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Blue Bird <a href="https://www.benzinga.com/quote/BLBD/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

BLBD

Earnings Summary: Blue Bird Q4

Enanta Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>) released its Q4 earnings on Monday, November 25, 2024 at 04:01 PM.
Here's what's important from the earnings announcement.
<h3>Earnings</h3>
Enanta Pharma beat estimated earnings by 4.0%, reporting an EPS of $-1.36 versus an estimate of $-1.41.
Revenue was down $4.33 million from the same period last year.
<h3>Earnings History Overview</h3>
Last quarter the company beat on EPS by $0.38 which was followed by a 1.0% increase in the share price the next day.
Here's a look at Enanta Pharma's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-1.45</td>
<td>-1.33</td>
<td>-1.19</td>
<td>-2</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-1.07</td>
<td>-1.47</td>
<td>-1.58</td>
<td>-1.33</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>17.18M</td>
<td>16.52M</td>
<td>21.28M</td>
<td>17.50M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>17.97M</td>
<td>17.05M</td>
<td>18.00M</td>
<td>18.93M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Enanta Pharma <a href="https://www.benzinga.com/quote/ENTA/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ENTA

Enanta Pharma Earnings Analysis: Q4 Recap

The Q4 earnings report for Central Garden &amp; Pet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENT#NASDAQ">CENT</a>) was released on Monday, November 25, 2024 at 04:02 PM.
Here's what investors need to know about the latest announcement.
<h3>Earnings</h3>
Central Garden &amp; Pet beat estimated earnings by 10.0%, reporting an EPS of $-0.18 versus an estimate of $-0.2.
Revenue was down $80.66 million from the same period last year.
<h3>Previous Earnings Records</h3>
The company beat on EPS by $0.11 in the last quarter, resulting in a 6.0% increase share price change the following day.
Here's a look at Central Garden &amp; Pet's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.21</td>
<td>0.80</td>
<td>-0.14</td>
<td>0.06</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.32</td>
<td>0.99</td>
<td>0.01</td>
<td>0.08</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>1.00B</td>
<td>887.42M</td>
<td>619.95M</td>
<td>735.32M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>996.35M</td>
<td>900.09M</td>
<td>634.53M</td>
<td>750.15M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Central Garden &amp; Pet <a href="https://www.benzinga.com/quote/CENT/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CENT

Central Garden & Pet: Q4 Earnings Insights

Leslie&#8217;s Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LESL#NASDAQ">LESL</a>) reported its fourth-quarter results after Monday's closing bell. Here's a look at the <a href="https://www.benzinga.com/pressreleases/24/11/g42174678/leslies-inc-announces-fourth-quarter-fiscal-2024-financial-results-provides-first-quarter-fiscal-2">details from the report. </a>
The Details: Leslie&#8217;s reported quarterly earnings of two cents per share which missed the analyst consensus estimate of 11 cents. Quarterly revenue came in at $397.9 million which missed the analyst consensus estimate of $405.19 million and is a decrease from sales of $432.37 million from the same period last year.
For the fiscal year 2024: 
<ul>
<li>Comparable sales decreased 8.8%. Non-comparable sales including acquisitions and new stores contributed $7.9 million for the year.</li>
<li>Gross profit decreased 13% to $476.8 million compared to $548.2 million in the prior year.</li>
<li>Gross margin decreased to 35.8% from 37.8% in the prior year period. </li>
<li>Operating income was $57.1 million compared to $102.2 million in the prior year.</li>
</ul>
Read Next: <a href="https://www.benzinga.com/trading-ideas/movers/24/11/41949068/bitcoin-could-reach-1-million-by-2037-economist-says-buy-of-a-lifetime-opportunity">Bitcoin Could Reach $1 Million By 2037, Economist Says: &#8216;Buy Of A Lifetime&#8217; Opportunity</a>
&#8220;Our fourth quarter results were in line with our revised expectations on the top-line, and we saw strong performance in our Pro segment with some continued softness in store traffic and larger-ticket and discretionary categories. Profitability was affected by deleverage from the sales decline and a one-time contract item, though we have remained disciplined on SG&amp;A expenses,&#8221; said Jason McDonell, CEO of Leslie&#8217;s. 
Outlook: Leslie&#8217;s expects first-quarter sales of between $169 million and $176 million and gross profit of $45 million to $48 million. 
LESL Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Leslie's shares are down 18.80% after-hours at $2.85 after gaining 10% during Monday&#8217;s regular trading session.
Read More:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41822473/trumps-potential-health-czar-robert-f-kennedy-jr-rattles-vaccine-stocks-shoot-first-reaction">Trump&#8217;s Potential &#8216;Health Czar&#8217; Robert F. Kennedy Jr. Rattles Vaccine Stocks: &#8216;Shoot First Reaction&#8217;</a></li>
</ul>
Photo: Oleg Gamulinskii from Pixabay

LESL

Leslie's Stock Drops After Q4 Results: Here's Why

SPIR

Spire Global Says Selected By LatConnect60 To Provide Global Navigation Satellite System Reflectometry Data And Soil Moisture Insights

The Company previously disclosed the retirement of E. Thomas Allen, Jr., the current Senior Executive Vice President and Chief Operating Officer of the Company and the Bank, effective as of January 31, 2025.

Management

CLBK

Columbia Financial Names Matthew Smith As Senior Executive Vice President And COO Of Company And The Bank Effective As Of November 25, 2024

Last week, Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) deepened its partnership with Anthropic through an additional $4 billion investment, bringing Amazon's total investment in the artificial intelligence research and development <a href="https://www.benzinga.com/24/11/42141911/amazon-and-anthropic-deepen-4-billion-ai-partnership-with-claude-35-launch">company to $8 billion. </a> 
The Details: As part of the investment, Anthropic <a href="https://www.aboutamazon.com/news/aws/amazon-invests-additional-4-billion-anthropic-ai">has named</a> Amazon Web Services as its primary training partner, in addition to continuing to be its primary cloud provider, and will use AWS Trainium and Inferentia chips to train and deploy its future foundation models.
Amazon also said Anthropic will work with AWS's chip-making division, Annapurna Labs, to continue the development of its custom Trainium chips.&nbsp;
Read More: <a href="https://www.benzinga.com/general/social-media/24/11/42119493/rumble-eyes-buying-bitcoin-could-it-be-the-next-microstrategy">Rumble CEO Considers Bitcoin Investment, Engages Michael Saylor As Shares Rally</a>
Expert Ideas: Bank of America Securities analyst Justin Post sees the expanded partnership as beneficial for both companies. Amazon needs a strong AI partner in order to ensure it can maintain competitive large language model (LLM) capabilities for AWS, and Anthropic likely needs more capital to compete with rival AI developer, OpenAI. 
Post also noted that the co-development of Amazon's Trainium chip capabilities could accelerate progress and build credibility for the chips among other AI customers. Also, Anthropic likely finds the potential cost savings for training and inference of its models attractive, given the company's current cash burn rate.&nbsp;
The analyst reiterated his view that the expanded partnership will prove to be mutually beneficial for Amazon and Anthropic.&nbsp;
"In our view, Amazon's growing investment will further advance Anthropic's capabilities, which should help capture incremental AI spend from Amazon's leading customer base," Post wrote.
Bank of America Securities maintained its Buy rating and $230 price objective on Amazon stock. 
Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Amazon shares ended Monday's session 2.2% higher at $201.45.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/24/11/41949068/bitcoin-could-reach-1-million-by-2037-economist-says-buy-of-a-lifetime-opportunity">Bitcoin Could Reach $1 Million By 2037, Economist Says: &#8216;Buy Of A Lifetime&#8217; Opportunity</a></li>
</ul>
Image: Shutterstock

Analyst Color

Large Cap

Analyst Ratings

Tech

AMZN

Amazon's $8 Billion Investment In AI Developer Anthropic 'Mutually Beneficial,' Says Analyst

Blue Bird (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLBD#NASDAQ">BLBD</a>) reported its Q4 earnings results on Monday, November 25, 2024 at 04:00 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Blue Bird missed estimated earnings by -16.0%, reporting an EPS of $0.77 versus an estimate of $0.92.
Revenue was up $47.25 million from the same period last year.
<h3>Analysis of Past Earnings</h3>
During the previous quarter, the company beat on EPS by $0.4, leading to a 0.0% increase share price change the next day.
Here's a look at Blue Bird's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.51</td>
<td>0.48</td>
<td>0.37</td>
<td>0.48</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.91</td>
<td>0.89</td>
<td>0.91</td>
<td>0.66</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>328.60M</td>
<td>298.41M</td>
<td>275.13M</td>
<td>290.11M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>333.37M</td>
<td>345.92M</td>
<td>317.66M</td>
<td>302.96M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Blue Bird <a href="https://www.benzinga.com/quote/BLBD/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Recap: Blue Bird Q4 Earnings

Woodward (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WWD#NASDAQ">WWD</a>) released its Q4 earnings on Monday, November 25, 2024 at 04:00 PM.
Here's what's important from the earnings announcement.
<h3>Earnings</h3>
Woodward beat estimated earnings by 13.0%, reporting an EPS of $1.41 versus an estimate of $1.25.
Revenue was up $77.42 million from the same period last year.
<h3>Previous Earnings Records</h3>
During the previous quarter, the company beat on EPS by $0.12, leading to a 17.0% drop share price change the next day.
Here's a look at Woodward's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.51</td>
<td>1.32</td>
<td>1.10</td>
<td>1.31</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.63</td>
<td>1.62</td>
<td>1.45</td>
<td>0.84</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>853.82M</td>
<td>807.00M</td>
<td>748.29M</td>
<td>765.35M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>847.69M</td>
<td>835.34M</td>
<td>786.73M</td>
<td>777.07M</td>
</tr>
</tbody>
</table>

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Guidance</h3>
Woodward management provided guidance for FY 2025, expecting earnings between $5.75 and $6.25 per share.
To track all earnings releases for Woodward <a href="https://www.benzinga.com/quote/WWD/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insights into Woodward Q4 Earnings

The Q4 earnings report for Enanta Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>) was released on Monday, November 25, 2024 at 04:01 PM.
Here's what investors need to know about the latest announcement.
<h3>Earnings</h3>
Enanta Pharma beat estimated earnings by 4.0%, reporting an EPS of $-1.36 versus an estimate of $-1.41.
Revenue was down $4.33 million from the same period last year.
<h3>Previous Earnings Records</h3>
During the previous quarter, the company beat on EPS by $0.38, leading to a 1.0% increase share price change the next day.
Here's a look at Enanta Pharma's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-1.45</td>
<td>-1.33</td>
<td>-1.19</td>
<td>-2</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-1.07</td>
<td>-1.47</td>
<td>-1.58</td>
<td>-1.33</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>17.18M</td>
<td>16.52M</td>
<td>21.28M</td>
<td>17.50M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>17.97M</td>
<td>17.05M</td>
<td>18.00M</td>
<td>18.93M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Enanta Pharma <a href="https://www.benzinga.com/quote/ENTA/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Enanta Pharma Q4 Earnings Assessment

Central Garden &amp; Pet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENT#NASDAQ">CENT</a>) announced its Q4 earnings on Monday, November 25, 2024 at 04:02 PM.
Here's a breakdown of the earnings report.
<h3>Earnings</h3>
Central Garden &amp; Pet beat estimated earnings by 10.0%, reporting an EPS of $-0.18 versus an estimate of $-0.2.
Revenue was down $80.66 million from the same period last year.
<h3>Past Earnings Performance</h3>
The company beat on EPS by $0.11 in the last quarter, resulting in a 6.0% increase share price change the following day.
Here's a look at Central Garden &amp; Pet's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.21</td>
<td>0.80</td>
<td>-0.14</td>
<td>0.06</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.32</td>
<td>0.99</td>
<td>0.01</td>
<td>0.08</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>1.00B</td>
<td>887.42M</td>
<td>619.95M</td>
<td>735.32M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>996.35M</td>
<td>900.09M</td>
<td>634.53M</td>
<td>750.15M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Central Garden &amp; Pet <a href="https://www.benzinga.com/quote/CENT/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Central Garden & Pet Earnings Report: Q4 Overview

Central Garden &amp; Pet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENTA#NASDAQ">CENTA</a>) released its Q4 earnings on Monday, November 25, 2024 at 04:02 PM.
Here's what's important from the earnings announcement.
<h3>Earnings</h3>
Central Garden &amp; Pet beat estimated earnings by 18.0%, reporting an EPS of $-0.18 versus an estimate of $-0.22.
Revenue was down $80.66 million from the same period last year.
<h3>Earnings History Overview</h3>
Last quarter the company beat on EPS by $0.02 which was followed by a 0.0% increase in the share price the next day.
Here's a look at Central Garden &amp; Pet's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.20</td>
<td>1.21</td>
<td>0.80</td>
<td>0.76</td>
<td>-0.14</td>
<td>-0.14</td>
<td>0.06</td>
<td>0.06</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.32</td>
<td>1.32</td>
<td>0.99</td>
<td>0.99</td>
<td>0.01</td>
<td>0.01</td>
<td>0.08</td>
<td>0.08</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>1.00B</td>
<td>1.00B</td>
<td>887.42M</td>
<td>883.42M</td>
<td>619.95M</td>
<td>619.95M</td>
<td>735.32M</td>
<td>735.32M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>996.35M</td>
<td>996.35M</td>
<td>900.09M</td>
<td>900.09M</td>
<td>634.53M</td>
<td>634.53M</td>
<td>750.15M</td>
<td>750.15M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Central Garden &amp; Pet <a href="https://www.benzinga.com/quote/CENTA/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CENTA

Earnings Summary: Central Garden & Pet Q4

MSGM

Motorsport Games Files For Mixed Shelf Of Up To $100M

Small-cap stocks are positioned for significant upside in 2025, driven by recovering earnings, potential corporate tax cuts, and favorable valuations, according to Brian Manby, investment strategy <a href="https://www.benzinga.com/exclusives?page=5">analyst at WisdomTree. </a>
In an exclusive interview with Benzinga, Manby shared his optimism for the Russell 2000 Index – as tracked by the iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) – which has already surged 23% year-to-date and <a href="https://www.benzinga.com/news/small-cap/24/11/42171130/russell-2000-dow-sp-500-all-achieve-record-highs-in-wall-streets-historic-day-bitcoin-gold-tumble-whats-driving-markets-monday">achieved record highs on Monday</a>, surpassing its previous peak from November 2021.
Manby said their domestic focus positions them as key beneficiaries of U.S.-centered policies, such as tax cuts and tariffs, while their relatively lower valuations create a compelling investment case for investors unwilling to excessively concentrate their portfolio on large caps.
<h3 class="wp-block-heading">Small Caps, Regional Banks: Positioned For Growth In 2025</h3>
The small-cap rally in 2024 has been particularly strong in the regional banking sector, with the SPDR S&amp;P Regional Banking ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KRE#NYSE">KRE</a>) soaring 35% this year. 
This outperformance was driven by combination of factors, including Federal Reserve rate cuts, U.S. economic resilience, and the anticipation of deregulation under a Republican-controlled Congress. 
The expert stressed that regional banks could continue to benefit in the coming year as policy tailwinds strengthen their earnings potential. 
"We think there&#8217;s a potential opportunity for a catch-up rally, hopefully bolstered by the deregulatory agenda of the incoming administration. We are pretty optimistic on small cap financials and regional banks in particular." he said.
&#8220;Any sort of pressure that the incoming administration can take off of the small cap financials operations would be really, really welcomed by the sector,&#8221; he added.
According to the house view, small-cap earnings projections for 2025 are optimistic, with potential upside tied to fiscal stimulus and economic expansion. Additionally, small-cap companies, with their U.S.-centric operations, stand to benefit significantly from proposed corporate tax rate reductions, such as a potential 15% tax rate championed by Republicans.
Manby also addressed the potential impact of tariffs under a Republican administration. 
"We think that the prospect of tariffs would be a bit of a greater headwind for large caps. Since small caps are more tied to the domestic economy, we think they would probably benefit," Manby said.
Also Read: <a href="https://www.benzinga.com/news/retail-sales/24/11/42170721/thanksgiving-dinner-gobbles-up-19-more-cash-this-year-many-holiday-hosts-already-regret-their-decision">Thanksgiving Dinner Gobbles Up 19% More Cash This Year, Many Holiday Hosts &#8216;Already Regret Their Decision&#8217;</a>
<h3 class="wp-block-heading">Small Caps Are Still Sharply Undervalued Compared To Large Caps</h3>
Discussing the valuation picture, Manby highlighted that small caps remain discounted relative to large caps, and that creates a strong opportunity for investors. 
&#8220;The Russell 2000 is still very discounted relative to the S&amp;P 500. It basically trades at about 2 standard deviations below its long term multiple versus the S&amp;P 500 and that gives us a lot of confidence in the valuation opportunity as well,&#8221; Manby stated.
Looking ahead to 2025, WisdomTree remains optimistic about the potential for small caps to outperform. "This is a great opportunity for U.S.-based investors seeking returns without paying lofty multiples," Manby said.
Furthermore, he highlighted that &#8220;ongoing potential rate cuts would certainly be beneficial within the broader small cap universe.&#8221;
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/42170135/its-the-most-wonderful-time-of-the-year-for-the-stock-market-history-says">&#8216;It&#8217;s The Most Wonderful Time Of The Year&#8217; For The Stock Market, History Says</a></li>
</ul>
Photo: Shutterstock

Sector ETFs

Broad U.S. Equity ETFs

Econ #s

ETFs

EXCLUSIVE: Small Caps Hit Records As Expert Says Russell 2000 'Still Very Discounted' Compared To S&P 500

Blue Bird (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLBD#NASDAQ">BLBD</a>) announced its Q4 earnings on Monday, November 25, 2024 at 04:00 PM.
Here's a breakdown of the earnings report.
<h3>Earnings</h3>
Blue Bird missed estimated earnings by -16.0%, reporting an EPS of $0.77 versus an estimate of $0.92.
Revenue was up $47.25 million from the same period last year.
<h3>Overview of Past Earnings</h3>
During the previous quarter, the company beat on EPS by $0.4, leading to a 0.0% increase share price change the next day.
Here's a look at Blue Bird's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.51</td>
<td>0.48</td>
<td>0.37</td>
<td>0.48</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.91</td>
<td>0.89</td>
<td>0.91</td>
<td>0.66</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>328.60M</td>
<td>298.41M</td>
<td>275.13M</td>
<td>290.11M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>333.37M</td>
<td>345.92M</td>
<td>317.66M</td>
<td>302.96M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Blue Bird <a href="https://www.benzinga.com/quote/BLBD/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Blue Bird Q4 Earnings Assessment

The earnings results for Woodward (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WWD#NASDAQ">WWD</a>) for Q4 were made public on Monday, November 25, 2024 at 04:00 PM.
Here's a comprehensive overview of the announcement.
<h3>Earnings</h3>
Woodward beat estimated earnings by 13.0%, reporting an EPS of $1.41 versus an estimate of $1.25.
Revenue was up $77.42 million from the same period last year.
<h3>Historical Earnings Summary</h3>
In the previous quarter, the company beat on EPS by $0.12, resulting in a 17.0% drop change in the share price the following day.
Here's a look at Woodward's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.51</td>
<td>1.32</td>
<td>1.10</td>
<td>1.31</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.63</td>
<td>1.62</td>
<td>1.45</td>
<td>0.84</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>853.82M</td>
<td>807.00M</td>
<td>748.29M</td>
<td>765.35M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>847.69M</td>
<td>835.34M</td>
<td>786.73M</td>
<td>777.07M</td>
</tr>
</tbody>
</table>

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Guidance</h3>
Woodward management provided guidance for FY 2025, expecting earnings between $5.75 and $6.25 per share.
To track all earnings releases for Woodward <a href="https://www.benzinga.com/quote/WWD/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Woodward Q4 Earnings Assessment

Mizuho Securities analyst Uy Ear has maintained their bullish stance on RNAC stock, giving a Buy rating today. Uy Ear has given his Buy rating due ...

Buy Rating for Cartesian Therapeutics Supported by Promising Descartes-08 Phase 2b Results and Upcoming Catalysts

TD Cowen analyst Tyler Van Buren maintained a Buy rating on Cartesian Therapeutics (RNAC – Research Report) today. The company's shares closed last...

TD Cowen Keeps Their Buy Rating on Cartesian Therapeutics (RNAC)

TD Cowen analyst Tyler Van Buren maintained a Buy rating on Cartesian Therapeutics (RNAC – Research Report) today. The company's shares opened toda...

TD Cowen Remains a Buy on Cartesian Therapeutics (RNAC)

Needham analyst Gil Blum has maintained their bullish stance on RNAC stock, giving a Buy rating today. Gil Blum has given his Buy rating due to a c...

Positive Outlook for Cartesian Therapeutics: Buy Rating Driven by Promising Study Results and Strategic Initiatives

In a report released today, Matthew Biegler from Oppenheimer maintained a Hold rating on Cartesian Therapeutics (RNAC – Research Report). The compa...

Cartesian Therapeutics (RNAC) Receives a Hold from Oppenheimer

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Cartesian Therapeutics (RNAC – Research Report), Allogene Therape...

Analysts Offer Insights on Healthcare Companies: Cartesian Therapeutics (RNAC), Allogene Therapeutics (ALLO) and Moderna (MRNA)

Cartesian Therapeutics, Inc. ( ($RNAC) ) has released its Q3 earnings. Here is a breakdown of the information Cartesian Therapeutics, Inc. presente...

Cartesian Therapeutics Reports Q3 2024 Financial Results

Cartesian Therapeutics: Uncertainty Remains

Thomas Smith, an analyst from Leerink Partners, reiterated the Buy rating on Cartesian Therapeutics (RNAC – Research Report). The associated price ...

Cartesian Therapeutics Receives Buy Rating After Promising Phase 2b Trial Results and Strategic Advancements

Cartesian Therapeutics (RNAC – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Gil Blum from...

Promising Developments and Strategic Positioning Drive Buy Rating for Cartesian Therapeutics

ALLO

ARGX

MRNA

RNAC

Health Care

Press Releases

Cartesian Therapeutics to Participate in Upcoming Investor Conferences

Cartesian Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 Trial of Next-Generation mRNA CAR-T Cell Therapy Descartes-15

Cartesian Therapeutics Announces New Employment Inducement Grant

Cartesian Therapeutics Receives FDA Rare Pediatric Disease Designation for Descartes-08 for the Treatment of Juvenile Dermatomyositis

Cartesian Therapeutics Announces New Employment Inducement Grants

Cartesian Therapeutics Announces Presentation of Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2024 MGFA Scientific Session of the AANEM Annual Meeting

Cartesian Therapeutics Announces Presentation at the Upcoming 66th ASH Annual Meeting

Cartesian Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Cartesian Therapeutics to Present Updated Data from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2nd Annual Cell Therapy for Autoimmune Disease Summit

Comments

Cartesian Therapeutics

Vendite allo scoperto

Cartesian Therapeutics (NASDAQ:RNAC) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO